Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
Polaryx Therapeutics, Inc. (PLYX)
Company Research
Source: GlobeNewswire
PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and healthcare providers. “On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments,” said Alex Yang, Chairman and Chief Executive Officer of Polaryx Therapeutics, Inc. “We are deeply committed to raising awareness of rare pediatric lysosomal storage disorders and developing disease-modifying, family-friendly therapies across multiple LSDs.” Polaryx continues to pursue its mission of addressing significant unmet medical needs in rare pediatric disorders by advancing the launch of SOTERIA, a pha
Show less
Read more
Impact Snapshot
Event Time:
PLYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLYX alerts
High impacting Polaryx Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLYX
News
- Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders [Yahoo! Finance]Yahoo! Finance
- Polaryx Therapeutics (PLYX) is now covered by Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™GlobeNewswire
- Polaryx Therapeutics Welcomes New Members of the Board of DirectorsGlobeNewswire
- Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch [Yahoo! Finance]Yahoo! Finance
PLYX
Sec Filings
- 2/20/26 - Form 4
- 2/5/26 - Form SCHEDULE
- 2/2/26 - Form 424B4
- PLYX's page on the SEC website